As Mimedx Group (MDXG) Stock Price Rose, Shareholder Dupont Capital Management Lowered Its Holding; Gilead Sciences (GILD) Share Price Declined While Avalon Global Asset Management Decreased Its Position

January 12, 2018 - By Linda Rogers

Avalon Global Asset Management Llc decreased its stake in Gilead Sciences Inc (GILD) by 40% based on its latest 2017Q3 regulatory filing with the SEC. Avalon Global Asset Management Llc sold 20,000 shares as the company’s stock declined 8.05% while stock markets rallied. The hedge fund held 30,000 shares of the health care company at the end of 2017Q3, valued at $2.43M, down from 50,000 at the end of the previous reported quarter. Avalon Global Asset Management Llc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $103.22 billion market cap company. The stock decreased 0.05% or $0.04 during the last trading session, reaching $79.02. About 4.97 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 12, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Dupont Capital Management Corp decreased its stake in Mimedx Group Inc (MDXG) by 31.62% based on its latest 2017Q3 regulatory filing with the SEC. Dupont Capital Management Corp sold 42,689 shares as the company’s stock rose 72.01% with the market. The institutional investor held 92,307 shares of the health care company at the end of 2017Q3, valued at $1.10 million, down from 134,996 at the end of the previous reported quarter. Dupont Capital Management Corp who had been investing in Mimedx Group Inc for a number of months, seems to be less bullish one the $1.54B market cap company. The stock decreased 0.57% or $0.08 during the last trading session, reaching $13.86. About 1.54M shares traded. MiMedx Group, Inc. (NASDAQ:MDXG) has risen 107.87% since January 12, 2017 and is uptrending. It has outperformed by 91.17% the S&P500.

Investors sentiment decreased to 1.97 in Q3 2017. Its down 0.05, from 2.02 in 2017Q2. It dived, as 21 investors sold MDXG shares while 44 reduced holdings. 48 funds opened positions while 80 raised stakes. 77.22 million shares or 15.28% more from 66.99 million shares in 2017Q2 were reported. Hbk Limited Partnership holds 0.01% or 74,900 shares. Bamco Inc Ny holds 64,800 shares. Thompson has 0.7% invested in MiMedx Group, Inc. (NASDAQ:MDXG). Eqis Cap Mgmt stated it has 0.01% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG). Great West Life Assurance Can has invested 0.01% in MiMedx Group, Inc. (NASDAQ:MDXG). Wildcat Mgmt Ltd Liability Co owns 500,000 shares. Natixis holds 14,845 shares or 0% of its portfolio. 22,374 are owned by Wms Ptnrs Ltd Liability Corp. Royal Bancshares Of Canada reported 225,804 shares. Moreover, Mason Street Advsrs Llc has 0.01% invested in MiMedx Group, Inc. (NASDAQ:MDXG) for 26,206 shares. 45,663 were accumulated by Bowling Port Ltd Llc. Metropolitan Life Ins has 69,927 shares. Tiedemann Wealth Mgmt Limited Liability owns 1.57 million shares. Gru One Trading Lp accumulated 0.02% or 140,854 shares. Us Bancorp De holds 0% of its portfolio in MiMedx Group, Inc. (NASDAQ:MDXG) for 1,707 shares.

Among 8 analysts covering MiMedx Group (NASDAQ:MDXG), 6 have Buy rating, 2 Sell and 0 Hold. Therefore 75% are positive. MiMedx Group had 26 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of MiMedx Group, Inc. (NASDAQ:MDXG) has “Buy” rating given on Tuesday, October 10 by Needham. The rating was maintained by First Analysis with “Overweight” on Wednesday, January 20. The stock has “Buy” rating by Needham on Thursday, July 27. The rating was initiated by UBS with “Sell” on Monday, December 12. The firm has “Buy” rating given on Tuesday, April 19 by Lake Street. The stock has “Underweight” rating by First Analysis on Tuesday, May 23. The rating was upgraded by Northland Capital to “Outperform” on Friday, October 30. The rating was maintained by Needham on Friday, December 1 with “Buy”. Needham initiated MiMedx Group, Inc. (NASDAQ:MDXG) on Thursday, August 3 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Thursday, July 13.

Analysts await MiMedx Group, Inc. (NASDAQ:MDXG) to report earnings on February, 22. They expect $0.11 earnings per share, up 120.00% or $0.06 from last year’s $0.05 per share. MDXG’s profit will be $12.21 million for 31.50 P/E if the $0.11 EPS becomes a reality. After $0.05 actual earnings per share reported by MiMedx Group, Inc. for the previous quarter, Wall Street now forecasts 120.00% EPS growth.

Dupont Capital Management Corp, which manages about $36.48B and $4.41B US Long portfolio, upped its stake in Dr Horton Inc (NYSE:DHI) by 27,512 shares to 73,039 shares, valued at $2.92 million in 2017Q3, according to the filing. It also increased its holding in Walgreens Boots Alliance Inc by 4,830 shares in the quarter, for a total of 66,925 shares, and has risen its stake in Ryman Hospitality Properties (NYSE:RHP).

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Gulf Bancshares (Uk) holds 412,202 shares or 0.45% of its portfolio. Pinnacle Associates Ltd owns 300,582 shares. Shamrock Asset Limited Liability Com reported 7,245 shares. Scotia Cap owns 168,294 shares. Intersect Cap Llc has invested 0.21% in Gilead Sciences, Inc. (NASDAQ:GILD). Pacific Heights Asset Management Limited Liability Corporation, a California-based fund reported 107,000 shares. Hanseatic Mngmt Svcs Inc holds 0.05% in Gilead Sciences, Inc. (NASDAQ:GILD) or 511 shares. Of Toledo Na Oh owns 0.6% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 29,035 shares. Amer National Com Tx invested in 0.82% or 192,875 shares. Brookmont Cap Mngmt owns 43,286 shares. Carl Domino owns 13,124 shares. Landscape Capital Mgmt Ltd Company accumulated 5,375 shares or 0.04% of the stock. Patten Patten Inc Tn has 2,590 shares for 0.02% of their portfolio. Provise Mgmt Group Ltd Llc holds 0.07% or 6,268 shares. Arrow Financial has invested 0.18% in Gilead Sciences, Inc. (NASDAQ:GILD).

Avalon Global Asset Management Llc, which manages about $132.23 million and $262.22 million US Long portfolio, upped its stake in Athenahealth Inc (NASDAQ:ATHN) by 5,780 shares to 45,780 shares, valued at $5.69M in 2017Q3, according to the filing. It also increased its holding in Macys Inc (Call) (NYSE:M) by 100,000 shares in the quarter, for a total of 300,000 shares, and has risen its stake in Cavium Inc (NASDAQ:CAVM).

Since August 1, 2017, it had 0 insider purchases, and 11 sales for $41.13 million activity. Alton Gregg H sold $1.14 million worth of stock or 15,000 shares. On Thursday, September 7 the insider Washington Robin L sold $4.40 million. Meyers James R also sold $4.99 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, August 31.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 EPS, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18 billion for 11.83 P/E if the $1.67 EPS becomes a reality. After $2.23 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 12 Hold. Therefore 60% are positive. Gilead Sciences had 111 analyst reports since July 29, 2015 according to SRatingsIntel. As per Wednesday, February 3, the company rating was maintained by Credit Suisse. The rating was upgraded by Piper Jaffray to “Overweight” on Thursday, November 5. Oppenheimer initiated Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, October 4 with “Hold” rating. The firm earned “Outperform” rating on Wednesday, November 2 by RBC Capital Markets. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by BMO Capital Markets on Monday, August 28. The firm earned “Buy” rating on Wednesday, February 3 by Standpoint Research. J.P. Morgan maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, July 24 with “Buy” rating. The firm earned “Buy” rating on Sunday, October 29 by Mizuho. Oppenheimer maintained it with “Outperform” rating and $120 target in Wednesday, July 29 report. As per Monday, June 12, the company rating was maintained by Jefferies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>